Pembrolizumab versus bevacizumab plus modified FOLFOX6 in metastatic MSI-H/dMMR colorectal cancer: a multicenter retrospective study with CT evaluation
Pembrolizumab monotherapy significantly improved survival over bevacizumab-based chemotherapy in metastatic MSI-H/dMMR CRC, with a manageable safety profile. These results reinforce PD-1 inhibitors as first-line therapy for this population, while highlighting tumor mutation burden (TMB) and tumor burden as critical biomarkers for personalized strategies.
Authors
- Jiaqi Chen
- Weiguang Yu (ORCID: https://orcid.org/0000-0003-4687-2624)
- Xiaobo Xia (ORCID: https://orcid.org/0000-0002-2785-3391)
- Xiaoyan Zhang (ORCID: https://orcid.org/0000-0002-6440-4245)
- Yang Zhao (ORCID: https://orcid.org/0000-0001-6984-1770)
- Haoyu Zhang (ORCID: https://orcid.org/0000-0001-5070-7547)
- Yunxiang Zhang (ORCID: https://orcid.org/0000-0002-3073-9979)
- Zhang Zhong (ORCID: https://orcid.org/0000-0002-5970-7727)
- Qiang Tang (ORCID: https://orcid.org/0000-0003-0239-6072)
- Jianghua Lou (ORCID: https://orcid.org/0000-0003-3967-2720)
- Yijie Zhang (ORCID: https://orcid.org/0009-0008-4165-6379)
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Henan Provincial People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.3389/fonc.2025.1570457
- Citations
- 1
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Science and Technology Department of Henan Province